Skip to content
Rituximab Maintenance Cuts Follicular Lymphoma Recurrence Risk In Half — Phase III PRIMA Study Results

Rituximab Maintenance Cuts Follicular Lymphoma Recurrence Risk In Half — Phase III PRIMA Study Results

Get the podcast

Patients in the PRIMA study who had achieved remissions for their follicular lymphoma by means of immunochemotherapy had only half the risk of recurrence if they also received maintenance therapy with

The Audio Journal of Oncology
Gilles Salles

Gilles Salles, University of Lyon

Patients in the PRIMA study who had achieved remissions for their follicular lymphoma by means of immunochemotherapy had only half the risk of recurrence if they also received maintenance therapy with rituximab for two years compared with those who did not.Gilles Sallesfrom the University of Lyon discussed his findings with Peter Goodwin during the 2010 European Hematology Association annual congress in Barcelona.

LISTEN

More from EHA 2010

All 2 interviews

This is the last of the 2 EHA 2010 interviews. See them all.

Related Episodes

Multiple Myeloma: Big Survival Gains From Novel Agents In The Real World

Multiple Myeloma: Big Survival Gains From Novel Agents In The Real World

Big improvements in survival among patients with multiple myeloma were reported at the European Hematology Association annual congress in Barcelona by Greek researchers looking at the past decade of t

28 Jun 2010